Search

Neglected tropical diseases (NTDs) are a group of diseases that disproportionately affect the poorest of the poor. While for years attention has focused on single diseases within this group, efforts during the past decade have resulted in their being grouped together to highlight that they are fundamentally diseases of neglected populations. The formation of a World Health Organization department to address these diseases consolidated the efforts of the many stakeholders involved. In the past decade, focus has shifted from the Millennium Development Goals (MDGs), where NTDs are not mentioned, to the Sustainable Development Goals (SDGs), where NTDs are not only mentioned, but clear indicators are provided to measure progress. It has also been a decade where many NTD programmes have scaled up rapidly thanks to work by affected countries through their master plans, the commitment of partners and the unprecedented donations of pharmaceutical manufacturers. This decade has also seen the scaling down of programmes and acknowledgement of the elimination of some diseases in several countries. Given the successes to date, the challenges identified over the past decade and the opportunities of the coming decade, the NTD Programme at the WHO is working with partners and stakeholders to prepare the new NTD roadmap for 2021 to 2030. The focus is on three major paradigm shifts: a change of orientation from process to impact, a change in technical focus from diseases to delivery platforms and a change from an external-based agenda and funding to a more country-led and funded implementation within health systems. This article reviews the past decade and offers a glimpse of what the future might hold for NTDs as a litmus test of SDG achievements., (© The Author(s) 2019. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

In most countries of Sub-Saharan Africa the control of lymphatic filariasis (LF) is based on annual mass drug administration (MDA) with a combination of ivermectin and albendazole, in order to interrupt transmission. We monitored the effect of four repeated MDAs with this combination, as implemented by the Tanzanian National Lymphatic Filariasis Elimination Programme (NLFEP), on the circulating filarial antigen (CFA) status of young schoolchildren. A new batch of Standard 1 pupils from 10 rural primary schools in Tanga Municipality were examined for CFA each year in September/October (691-848 children per survey; mean age of 7.5-8.1 years), from immediately before the first MDA until eight months after the fourth MDA. The overall pre-MDA prevalence of CFA was 25.2%. Only minor and non-significant change in prevalence was seen after the first two MDAs. However, this was followed by substantial and statistically significant decreases in subsequent surveys, and eight months after the fourth MDA the prevalence was only 6.4%. Continuous entomological surveillance in a village accommodating one of the schools showed progressive decrease in transmission right from the first MDA. The usefulness of screening young schoolchildren for CFA as a tool for monitoring the impact of MDA on LF transmission is discussed.